Osteoporosis Drugs Market Size, Share, Trends, Growth and Forecast 2032

Osteoporosis Drugs Market

Osteoporosis Drugs Market: By Drug Class (Bisphosphonates, Calcitonin, Rank Ligand Inhibitors, Parathyroid Hormone Therapy (Pth), Selective Estrogen Receptor Modulators (Serms), Others), By Gender (Male, Female), And By Region: Global Industry Analysis, Size, Share, Growth, Latest Trends, Regional Outlook, and Forecast 2024 - 2032

Category: Pharmaceutical Report Format : PDF Pages: 140 Report Code: ZMR-342 Published Date: Dec-2024 Status : Published
Market Size in 2023 Market Forecast in 2032 CAGR (in %) Base Year
USD 16.21 Billion USD 25.36 Billion 5.1% 2023

Table Of Content

  • Chapter No. 1 Introduction
    • 1.1. Report Description
      • 1.1.1. Purpose of the Report
      • 1.1.2. USP & Key Offerings
    • 1.2. Key Benefits for Stakehulders
    • 1.3. Target Audience
    • 1.4. Report Scope
  • Chapter No. 2 Executive Summary
    • 2.1. Key Findings
      • 2.1.1. Top Investment Pockets
        • 2.1.1.1. Market Attractiveness Analysis, By Drug Class
        • 2.1.1.2. Market Attractiveness Analysis, By Gender
        • 2.1.1.3. Market Attractiveness Analysis, By Region
    • 2.2. Market Snapshot
    • 2.3. Global Osteoporosis Drugs Market, 2016 – 2028 (USD Billion)
    • 2.4. Insights from Primary Respondents
  • Chapter No. 3 COVID 19 Impact Analysis
    • 3.1. Impact Assessment of COVID-19 Pandemic, By Region
      • 3.1.1. North America
      • 3.1.2. Europe
      • 3.1.3. Asia Pacific
      • 3.1.4. Latin America
      • 3.1.5. The Middle-East and Africa
    • 3.2. Quarterly Market Revenue and Forecast by Region 2020 & 2021
    • 3.3. Pre COVID-19 Market Revenue, By Region, 2016-2019 (USD Billion)
    • 3.4. Post COVID-19 Market Revenue, By Region, 2020-2028 (USD Billion)
    • 3.5. Key Strategies Undertaken by Companies to Tackle COVID-19
      • 3.5.1. Company Quarterly Revenue Analysis, 2019 & 2020
    • 3.6. Short Term Dynamics
    • 3.7. Long Term Dynamics
  • Chapter No. 4 Osteoporosis Drugs Market – Drug Class Segment Analysis
    • 4.1. Overview
      • 4.1.1. Market Revenue Share, By Drug Class, 2020 & 2028
    • 4.2. Bisphosphonates
      • 4.2.1. Market Size and Forecast, By Region (USD Billion)
      • 4.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.2.3. Key Market Trends, Growth Factors, & Opportunities
    • 4.3. Selective Estrogen Receptor Modulators (SERMs)
      • 4.3.1. Market Size and Forecast, By Region (USD Billion)
      • 4.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.3.3. Key Market Trends, Growth Factors, & Opportunities
    • 4.4. Parathyroid Hormone Therapy (PTH)
      • 4.4.1. Market Size and Forecast, By Region (USD Billion)
      • 4.4.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.4.3. Key Market Trends, Growth Factors, & Opportunities
    • 4.5. Rank Ligand Inhibitors
      • 4.5.1. Market Size and Forecast, By Region (USD Billion)
      • 4.5.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.5.3. Key Market Trends, Growth Factors, & Opportunities
    • 4.6. Calcitonin
      • 4.6.1. Market Size and Forecast, By Region (USD Billion)
      • 4.6.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.6.3. Key Market Trends, Growth Factors, & Opportunities
    • 4.7. Others
      • 4.7.1. Market Size and Forecast, By Region (USD Billion)
      • 4.7.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.7.3. Key Market Trends, Growth Factors, & Opportunities
  • Chapter No. 5 Osteoporosis Drugs Market – Gender Segment Analysis
    • 5.1. Overview
      • 5.1.1. Market Revenue Share, By Gender, 2020 & 2028
    • 5.2. Male
      • 5.2.1. Market Size and Forecast, By Region (USD Billion)
      • 5.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 5.2.3. Key Market Trends, Growth Factors, & Opportunities
    • 5.3. Female
      • 5.3.1. Market Size and Forecast, By Region (USD Billion)
      • 5.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 5.3.3. Key Market Trends, Growth Factors, & Opportunities
  • Chapter No. 6 Plant Factory Grow Market – Region Segment Analysis
    • 6.1. Overview
      • 6.1.1. Global Market Revenue Share, By Region, 2020 & 2028
      • 6.1.2. Global Market Revenue, By Region, 2016 – 2028 (USD Billion)
    • 6.2. North America
      • 6.2.1. North America Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 6.2.2. North America Market Revenue, By Drug Class, 2016 – 2028
      • 6.2.3. North America Market Revenue, By Gender, 2016 – 2028
      • 6.2.5. U.S.
        • 6.2.5.1. U.S. Market Revenue, By Drug Class, 2016 – 2028
        • 6.2.5.2. U.S. Market Revenue, By Gender, 2016 – 2028
      • 6.2.6. Canada
        • 6.2.6.1. Canada Market Revenue, By Drug Class, 2016 – 2028
        • 6.2.6.2. Canada Market Revenue, By Gender, 2016 – 2028
      • 6.2.7. Mexico
        • 6.2.7.1. Mexico Market Revenue, By Drug Class, 2016 – 2028
        • 6.2.7.2. Mexico Market Revenue, By Gender, 2016 – 2028
    • 6.3. Europe
      • 6.3.1. Europe Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 6.3.2. Europe Market Revenue, By Drug Class, 2016 – 2028
      • 6.3.3. Europe Market Revenue, By Gender, 2016 – 2028
      • 6.3.5. Germany
        • 6.3.5.1. Germany Market Revenue, By Drug Class, 2016 – 2028
        • 6.3.5.2. Germany Market Revenue, By Gender, 2016 – 2028
      • 6.3.6. France
        • 6.3.6.1. France Market Revenue, By Drug Class, 2016 – 2028
        • 6.3.6.2. France Market Revenue, By Gender, 2016 – 2028
      • 6.3.7. U.K.
        • 6.3.7.1. U.K. Market Revenue, By Drug Class, 2016 – 2028
        • 6.3.7.2. U.K. Market Revenue, By Gender, 2016 – 2028
      • 6.3.8. Italy
        • 6.3.8.1. Italy Market Revenue, By Drug Class, 2016 – 2028
        • 6.3.8.2. Italy Market Revenue, By Gender, 2016 – 2028
      • 6.3.9. Spain
        • 6.3.9.1. Spain Market Revenue, By Drug Class, 2016 – 2028
        • 6.3.9.2. Spain Market Revenue, By Gender, 2016 – 2028
      • 6.3.10. Rest of Europe
        • 6.3.10.1. Rest of Europe Market Revenue, By Drug Class, 2016 – 2028
        • 6.3.10.2. Rest of Europe Market Revenue, By Gender, 2016 – 2028
    • 6.4. Asia Pacific
      • 6.4.1. Asia Pacific Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 6.4.2. Asia Pacific Market Revenue, By Drug Class, 2016 – 2028
      • 6.4.3. Asia Pacific Market Revenue, By Gender, 2016 – 2028
      • 6.4.5. China
        • 6.4.5.1. China Market Revenue, By Drug Class, 2016 – 2028
        • 6.4.5.2. China Market Revenue, By Gender, 2016 – 2028
      • 6.4.6. Japan
        • 6.4.6.1. Japan Market Revenue, By Drug Class, 2016 – 2028
        • 6.4.6.2. Japan Market Revenue, By Gender, 2016 – 2028
      • 6.4.7. India
        • 6.4.7.1. India Market Revenue, By Drug Class, 2016 – 2028
        • 6.4.7.2. India Market Revenue, By Gender, 2016 – 2028
      • 6.4.8. South Korea
        • 6.4.8.1. South Korea Market Revenue, By Drug Class, 2016 – 2028
        • 6.4.8.2. South Korea Market Revenue, By Gender, 2016 – 2028
      • 6.4.9. South-East Asia
        • 6.4.9.1. South-East Asia Market Revenue, By Drug Class, 2016 – 2028
        • 6.4.9.2. South-East Asia Market Revenue, By Gender, 2016 – 2028
      • 6.4.10. Rest of Asia Pacific
        • 6.4.10.1. Rest of Asia Pacific Market Revenue, By Drug Class, 2016 – 2028
        • 6.4.10.2. Rest of Asia Pacific Market Revenue, By Gender, 2016 – 2028
    • 6.5. Latin America
      • 6.5.1. Latin America Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 6.5.2. Latin America Market Revenue, By Drug Class, 2016 – 2028
      • 6.5.3. Latin America Market Revenue, By Gender, 2016 – 2028
      • 6.5.5. Brazil
        • 6.5.5.1. Brazil Market Revenue, By Drug Class, 2016 – 2028
        • 6.5.5.2. Brazil Market Revenue, By Gender, 2016 – 2028
      • 6.5.6. Argentina
        • 6.5.6.1. Argentina Market Revenue, By Drug Class, 2016 – 2028
        • 6.5.6.2. Argentina Market Revenue, By Gender, 2016 – 2028
      • 6.5.7. Rest of Latin America
        • 6.5.7.1. Rest of Latin America Market Revenue, By Drug Class, 2016 – 2028
        • 6.5.7.2. Rest of Latin America Market Revenue, By Gender, 2016 – 2028
    • 6.6. The Middle-East and Africa
      • 6.6.1. The Middle-East and Africa Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 6.6.2. The Middle-East and Africa Market Revenue, By Drug Class, 2016 – 2028
      • 6.6.3. The Middle-East and Africa Market Revenue, By Gender, 2016 – 2028
      • 6.6.5. GCC Countries
        • 6.6.5.1. GCC Countries Market Revenue, By Drug Class, 2016 – 2028
        • 6.6.5.2. GCC Countries Market Revenue, By Gender, 2016 – 2028
      • 6.6.6. South Africa
        • 6.6.6.1. South Africa Market Revenue, By Drug Class, 2016 – 2028
        • 6.6.6.2. South Africa Market Revenue, By Gender, 2016 – 2028
      • 6.6.7. Rest of Middle-East Africa
        • 6.6.7.1. Rest of Middle-East Africa Market Revenue, By Drug Class, 2016 – 2028
        • 6.6.7.2. Rest of Middle-East Africa Market Revenue, By Gender, 2016 – 2028
  • Chapter No. 7: Osteoporosis Drugs Market – Industry Analysis
    • 7.1. Introduction
    • 7.2. Market Drivers
      • 7.2.1. Driving Factor 1 Analysis
      • 7.2.2. Driving Factor 2 Analysis
    • 7.3. Market Restraints
      • 7.3.1. Restraining Factor Analysis
    • 7.4. Market Opportunities
      • 7.4.1. Market Opportunity Analysis
    • 7.5. Porter’s Five Forces Analysis
    • 7.6. PEST Analysis
    • 7.7. Regulatory Landscape
    • 7.8. By Gender Landscape
    • 7.9. Regional Market Trends
      • 7.9.1. North America
      • 7.9.2. Europe
      • 7.9.3. Asia Pacific
      • 7.9.4. Latin America
      • 7.9.5. The Middle-East and Africa
    • 7.10. Pricing Analysis
    • 7.11. Value Chain Analysis
    • 7.12. Downstream Buyers
    • 7.13. Distributors/Traders List
  • Chapter No. 8: Competitive Landscape
    • 8.1. Company Market Share Analysis – 2019
      • 8.1.1. Global Osteoporosis Drugs Market: Company Market Share, 2019
      • 8.1.2. Global Osteoporosis Drugs Market, Company Market Revenue, 2016 – 2019 (USD Billion)
      • 8.1.3. Global Osteoporosis Drugs Market, Company Y-o-Y Growth, 2017 – 2019 (%)
      • 8.1.4. Global Osteoporosis Drugs Market: Radar Determinant Chart, 2019
    • 8.2. Strategic Developments
      • 8.2.1. Acquisitions & Mergers
      • 8.2.2. New Product Launch
      • 8.2.3. Regional Expansion
    • 8.3. Company Strategic Developments – Heat Map Analysis
  • Chapter No. 9: Company Profiles
    • 9.1. Novartis International AG
      • 9.1.1. Company Overview
      • 9.1.2. Key Executives
      • 9.1.3. Product Portfolio
      • 9.1.4. Financial Overview
      • 9.1.5. Operating Business Segments
      • 9.1.6. Business Performance
      • 9.1.7. Recent Developments
    • 9.2. Eli Lilly Amgen Inc.
    • 9.3 Forteo
    • 9.4 Novo Nordisk A/S.
    • 9.5 F. Hoffmann La Roche Ltd.
    • 9.6 Company, Merck & Co, Inc.
    • 9.7 Actavis plc
    • 9.8 Pfizer, Inc
    • 9.9 Teva Pharmaceutical Industries Ltd.
    • 9.10 Company 10
  • Chapter No. 10: Marketing Strategy Analysis
    • 10.1. Marketing Channel
    • 10.2. Direct Marketing
    • 10.3. Indirect Marketing
    • 10.4. Marketing Channel Development Trends
    • 10.5. Economic/Pulitical Environmental Change
  • Chapter No. 11: Research Methodology
    • 11.1. Research Methodology
    • 11.2. Phase I - Secondary Research
    • 11.3. Phase II - Data Modeling
      • 11.3.1. Company Share Analysis Model
      • 11.3.2. Revenue Based Modeling
    • 11.4. Phase III - Primary Research
    • 11.5. Research Limitations
      • 11.5.1. Assumptions

Table Of Figures

List of Figures 

FIG NO. 1. Market Attractiveness Analysis, By Drug Class
FIG NO. 2. Market Attractiveness Analysis, By Gender
FIG NO. 3. Market Attractiveness Analysis, By Region
FIG NO. 4. Global  Osteoporosis Drugs Market Revenue, 2016 – 2028 (USD Billion)
FIG NO. 5. Impact of COVID-19 Pandemic in North America Countries
FIG NO. 6. Market Revenue Share, By Drug Class, 2020 & 2028 
FIG NO. 7. Global  Osteoporosis Drugs Market for Bisphosphonates, Revenue (USD Billion) 2016 – 2028
FIG NO. 8. Comparative Revenue Analysis of  Osteoporosis Drugs Market for Bisphosphonates, By Country, 2020 & 2028
FIG NO. 9. Global  Osteoporosis Drugs Market for Selective Estrogen Receptor Modulators (SERMs), Revenue (USD Billion) 2016 – 2028
FIG NO. 10. Comparative Revenue Analysis of  Osteoporosis Drugs Market for Selective Estrogen Receptor Modulators (SERMs), By Country, 2020 & 2028
FIG NO. 9. Global  Osteoporosis Drugs Market for Parathyroid Hormone Therapy (PTH) , Revenue (USD Billion) 2016 – 2028
FIG NO. 10. Comparative Revenue Analysis of  Osteoporosis Drugs Market for Parathyroid Hormone Therapy (PTH) , By Country, 2020 & 2028
FIG NO. 11. Global  Osteoporosis Drugs Market for Rank Ligand Inhibitors, Revenue (USD Billion) 2016 – 2028
FIG NO. 12. Comparative Revenue Analysis of  Osteoporosis Drugs Market for Rank Ligand Inhibitors, By Country, 2020 & 2028
FIG NO. 13. Global  Osteoporosis Drugs Market for Others, Revenue (USD Billion) 2016 – 2028
FIG NO. 14. Comparative Revenue Analysis of  Osteoporosis Drugs Market for Others, By Country, 2020 & 2028
FIG NO. 15. Market Revenue Share, By Gender, 2020 & 2028
FIG NO. 16. Global  Osteoporosis Drugs Market for Male, Revenue (USD Billion) 2016 – 2028
FIG NO. 17. Comparative Revenue Analysis of  Osteoporosis Drugs Market for Male, By Country, 2020 & 2028 
FIG NO. 18. Global  Osteoporosis Drugs Market for Female, Revenue (USD Billion) 2016 – 2028
FIG NO. 19. Comparative Revenue Analysis of  Osteoporosis Drugs Market for Female, By Country, 2020 & 2028
FIG NO. 20. Global  Osteoporosis Drugs Market for Others, Revenue (USD Billion) 2016 – 2028
FIG NO. 21. Comparative Revenue Analysis of  Osteoporosis Drugs Market for Others, By Country, 2020 & 2028
FIG NO. 22. Global  Osteoporosis Drugs Market Revenue Share, By Region, 2020 & 2028
FIG NO. 23. North America  Osteoporosis Drugs Market Revenue, 2016 - 2028 (USD Billion)
FIG NO. 24. Porter’s Five Forces Analysis for Global  Osteoporosis Drugs Market
FIG NO. 25. PEST Analysis for Global  Osteoporosis Drugs Market
FIG NO. 26. Pricing Analysis for Global  Osteoporosis Drugs Market
FIG NO. 27. Value Chain Analysis for Global  Osteoporosis Drugs Market
FIG NO. 28. Company Share Analysis, 2019
FIG NO. 29. Radar Determinant Chart, 2019
FIG NO. 30. Company Strategic Developments – Heat Map Analysis
FIG NO. 31. Business Segment Revenue Share, 2020 (%)
FIG NO. 32. Geographical Segment Revenue Share, 2020 (%)
FIG NO. 33. Market Channels
FIG NO. 34. Marketing Channel Development Trend
FIG NO. 35. Growth in World Gross Product, 2008-2018
FIG NO. 36. Research Methodology – Detailed View
FIG NO. 37. Research Methodology
 


Table Of Tables

List of Tables 

TABLE NO. 1. Global  Osteoporosis Drugs Market: Snapshot
TABLE NO. 2. Quarterly  Osteoporosis Drugs Market Revenue by Region, 2020
TABLE NO. 3. Quarterly  Osteoporosis Drugs Market Revenue Forecast by Region, 2021
TABLE NO. 4. Pre COVID-19 Market Revenue, By Region, 2016-2019 (USD Billion) 
TABLE NO. 5. Post COVID-19 Market Revenue, By Region, 2020-2028 (USD Billion) 
TABLE NO. 6. Global  Osteoporosis Drugs Market for Bisphosphonates, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 7. Global  Osteoporosis Drugs Market for Selective Estrogen Receptor Modulators (SERMs), by Region, 2016 – 2028 (USD Billion)
TABLE NO. 8. Global  Osteoporosis Drugs Market for Parathyroid Hormone Therapy (PTH) , by Region, 2016 – 2028 (USD Billion)
TABLE NO. 9. Global  Osteoporosis Drugs Market for Rank Ligand Inhibitors, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 10. Global  Osteoporosis Drugs Market for Others, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 11. Global  Osteoporosis Drugs Market for Male, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 12 Global  Osteoporosis Drugs Market for Female, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 13 Global  Osteoporosis Drugs Market Revenue, By Region, 2016 – 2028 (USD Billion)
TABLE NO. 14. North America  Osteoporosis Drugs Market Revenue, By Country, 2016 – 2028 (USD Billion)
TABLE NO. 15. North America  Osteoporosis Drugs Market Revenue, By Drug Class, 2016 – 2028 (USD Billion)
TABLE NO. 16. North America  Osteoporosis Drugs Market Revenue, By Drug Class, 2016 – 2028 (USD Billion)
TABLE NO. 17. U.S.  Osteoporosis Drugs Market Revenue, By Drug Class, 2016 – 2028 (USD Billion)
TABLE NO. 18. U.S.  Osteoporosis Drugs Market Revenue, By Drug Class, 2016 – 2028 (USD Billion)
TABLE NO. 19. Canada  Osteoporosis Drugs Market Revenue, By Drug Class, 2016 – 2028 (USD Billion)
TABLE NO. 20. Canada  Osteoporosis Drugs Market Revenue, By Drug Class, 2016 – 2028 (USD Billion)
TABLE NO. 21. Mexico  Osteoporosis Drugs Market Revenue, By Drug Class, 2016 – 2028 (USD Billion)
TABLE NO. 22. Mexico  Osteoporosis Drugs Market Revenue, By Drug Class, 2016 – 2028 (USD Billion)
TABLE NO. 23. Drivers for the  Osteoporosis Drugs Market: Impact Analysis
TABLE NO. 24. Restraints for the  Osteoporosis Drugs Market: Impact Analysis
TABLE NO. 25. Major Buyers of  Osteoporosis Drugs Market
TABLE NO. 26. Distributors/Traders List of  Osteoporosis Drugs Market
TABLE NO. 27. Global  Osteoporosis Drugs Market, Company Market Revenue, 2016 – 2019 (USD Billion)
TABLE NO. 28: Global  Osteoporosis Drugs Market, Company Y-o-Y Growth, 2017 – 2019 (USD Billion)   


 

Methodology

FrequentlyAsked Questions

Osteoporosis Drugs Market size is set to expand from $ 16.21 Billion in 2023

Osteoporosis Drugs Market size is set to expand from $ 16.21 Billion in 2023 to $ 25.36 Billion by 2032, with an anticipated CAGR of around 5.1% from 2024 to 2032.

Factors such as an unprecedented rise in the disease resulted in the high demand for drugs in prophylaxis and treatment of osteoporosis thus widening the growth potential over the coming years. Moreover, the geriatric population possessing high susceptibility for osteoporosis is further presumed to propel the high demand.

North America in 2020 ruled the Osteoporosis Drugs Market and was believed to be the highest income-generating area all over the globe.

The major players that are comprised in Osteoporosis Drugs Market are Novartis International AG, Eli Lilly Amgen Inc., Forteo, Novo Nordisk A/S., F. Hoffmann La Roche Ltd., and Company, Merck & Co, Inc., Actavis plc, Pfizer, Inc, and Teva Pharmaceutical Industries Ltd.

  • zion payment modes

List of Contents

Market InsightsGlobal Market Overview Growth Factors Report ScopeSegment Analysis Preview Regional Analysis PreviewKey Market Players Competitive LandscapeThe global Market is segmented as follows:By Region

HappyClients